Stocks · News reference
Annexon Reports Early Strength Improvement And Clinically Meaningful Disability Reduction With Tanruprubart In First Ten US And European Guillain-Barré Syndrome Patients From Ongoing FORWARD Study
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved Targeted Therapy to
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Annexon Announces Presentations On Vonaprument For Geographic Atrophy At Retina Society Meeting; Says Phase 3 Results Expected In Q4 2026
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14
Citizens Upgrades Annexon to Market Perform
Citizens analyst Jonathan Wolleben upgrades Annexon (NASDAQ:ANNX) from Market Underperform to Market Perform.